TargED Presents Positive Clinical Results for TGD001 from Phase 1 Study During Oral Session at ASH 2025

We are excited to announce positive results from a Phase 1 study for TargED’s lead investigational thrombolytic fusion protein, TGD001, in an oral presentation at #ASH25 in Orlando, Florida today.
The first-in-human clinical trial demonstrated that TGD001 is safe and was well tolerated with no spontaneous bleeding events across four ascending dose cohorts.

TargED plans to initiate two Phase 1/2 clinical proof-of-concept studies evaluating TGD001 as a potential treatment for patients with acute ischemic stroke (AIS) and thrombotic microangiopathies (TMAs), including immune thrombotic thrombocytopenic purpura (iTTP).